© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
A discussion ofJAK2-directed therapies, their roles in treatment, and the key clinical trials guiding their use in myeloproliferative neoplasms. Also discussed are some relevant data recently presented at ASCO.
July 14th 2021
Experts discuss the differences between essential thrombocythemia [ET], polycythemia vera [PV], and myelofibrosis [MF] and refinement of diagnosis.
Dr Verstovsek and Dr Kuykendall discuss the limitations of past treatments for MPNs.
A discussion of the role of the JAK2 mutation and other factors in the development of MPNs.
The progression of disease in MPNs and how genetic testing may inform therapy.
July 21st 2021
Response criteria, quality of life issues, and therapeutic options including ruxolitinib, hydroxyurea, and interferon are discussed in the context of ET.
Additional treatment options for low- and high-risk patients with MPNs are discussed.
Efficacy and safety profiles of therapies for PV are discussed, along with results of the RESPONSE and RESPONSE-2 studies.
A discussion of JAK inhibitors, risk models, quality of life, splenomegaly, and other issues in treating patients with MF.
July 28th 2021
Alternative dosing schedules and the use of JAK inhibitors for patients with MPNs in the second-line setting are explored.
Combination trials and new agents for MPNs, such as parsaclisib and momelotinib, are discussed in the context of recent ASCO presentations.